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Abstract 
Purpose: Despite an explosion of translational research to exploit biomarkers in diagnosis, prediction and prog-
nosis, the impact of biomarkers on clinical practice has been limited. The elusiveness of clinical utility may partly 
originate when validation studies are planned, from a failure to articulate precisely how the biomarker, if successful, 
will improve clinical decision-making for patients. Clarifying what performance would suffice if the test is to improve 
medical care makes it possible to design meaningful validation studies. But methods for tackling this part of validation 
study design are undeveloped, because it demands uncomfortable judgments about the relative values of good and 
bad outcomes resulting from a medical decision.
Methods: An unconventional use of “number needed to treat” (NNT) can structure communication for the trial 
design team, to elicit purely value-based outcome tradeoffs, conveyed as the endpoints of an NNT “discomfort range”. 
The study biostatistician can convert the endpoints into desired predictive values, providing criteria for designing a 
prospective validation study. Next, a novel “contra-Bayes” theorem converts those predictive values into target sen-
sitivity and specificity criteria, to guide design of a retrospective validation study. Several examples demonstrate the 
approach.
Conclusion: In practice, NNT-guided dialogues have contributed to validation study planning by tying it closely 
to specific patient-oriented translational goals. The ultimate payoff comes when the report of the completed study 
includes motivation in the form of a biomarker test framework directly reflecting the clinical decision challenge to be 
solved. Then readers will understand better what the biomarker test has to offer patients.
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Background
Motivation: disconnection between biomarker studies 
and clinical utility
Despite an explosion of research studies aiming to exploit 
biomarkers for eventual clinical application, their trans-
lation into impact on actual clinical practice has been 
minimal. Early detection biomarkers have mostly been 
unsuccessful, prognostic biomarkers are infrequently 
used in clinical decision making, surrogate endpoint 
biomarkers are rarely accepted for phase III clinical tri-
als, and predictive biomarkers distinguishing patients 
who will benefit from a treatment have been difficult to 
validate. Tsilidis et  al. [1] studied 98 meta-analyses of 
non-genetic biomarkers in association with cancer risk, 
finding that only 12 passed their criteria for believabil-
ity. Hayes et al. [2] laments “the field of tumor biomarker 
research has been chaotic and haphazard, leading to 
many published papers in the peer-reviewed literature, 
but very few markers that truly have clinical utility”. Ran-
sohoff asks [3] “Is it the normal stop-and-start of science? 
Or is there some systemic problem with the process 
that we currently use to discover and develop markers?” 
The skepticism has motivated individuals, committees 
and consortiums to identify problems, and promulgate 
guidelines for performing and reporting research, and 
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for critical reviewing [4–14]. Ioannidis and Khoury [15], 
in lamenting a history of poor validation in “omics” bio-
marker studies, list six validation criteria. The last one 
listed is clinical utility: “Does the use of the discovered 
information improve clinical outcomes?” Indeed, the 
desirability of defining the intended clinical use (“action-
ability”) frequently receives mention, but guidance how 
to define it in practice is scarce. Consequently, most 
biomarker studies use statistical criteria, such as P val-
ues, hazard ratios, sensitivity and specificity, with only a 
murky relationship to the medical decisions and human 
health goals that physicians want to achieve with the bio-
marker. The planning, study design and presentation of 
biomarker validation study results usually omit concrete 
consideration of the desired improvements in decisions 
on behalf of patients.
Investigators should be able to state the intended clini-
cal benefit: what specific improvement in decisions about 
treatment, screening or prevention the investigators hope 
the biomarker will achieve. The motivation of this work 
is to give clinical investigation teams a method to help 
articulate and clarify the goal for future patients. When 
such a goal cannot be stated, the justification of a study is 
rightfully called into question.
Outline of approach and applications
The method introduced here produces quantitative crite-
ria, chosen so that the ethical tradeoffs between false pos-
itives and false negatives are easy to visualize in concrete 
terms. A biomarker validation study justified by an artic-
ulated patient-relevant quantitative goal will have suit-
able design and sample sizes. After completing the study, 
a reader can compare that original justification for the 
design with the study results, making it clear whether the 
new test should be adopted. Utilizing this method should 
reduce pointless biomarker validation studies, improve 
relevance of worthy studies, ensure adequate power for 
the purpose, and sharpen the interpretation of results.
The tools provided here can open communications 
within a trial design team to help them state perfor-
mance criteria that correspond to genuine clinical useful-
ness. An unconventional use of the “number needed to 
treat” (NNT) concept provides a simple method to elicit 
clear specification of the intended medical use of the 
biomarker. An NNT “discomfort range” helps define the 
needed predictive values, providing meaningful criteria 
for the design of a prospective validation study. To guide 
the design of a retrospective validation study, a “con-
tra-Bayes” theorem converts the predictive values into 
minimum requirements for sensitivity and specificity. 
Figure 1 and Table 1 present overviews. Several examples 
from cancer biomarker research illustrate the benefits 
and some remaining challenges. Interactive web pages 
driven by open-source software deliver easily accessible 
guidance.
Methods
Setting and terminology for medical decision‑making 
and testing
Medicine requires making decisions in the face of imper-
fect information. The Bayesian framework [16] is espe-
cially well suited for medical decision-making, with a 
long history [17–19]. We consider the simplest binary 
medical decision: an action to take or refrain from. The 
action contemplated may be a medical treatment, a costly 
or risky diagnostic procedure, an onerous, costly moni-
toring schedule for early detection, or enrolling a patient 
onto a clinical trial. The following terminology covers 
these cases.
Suppose some biological characteristic of a patient 
would determine our choice between acting or waiting if 
we knew its status: either BestToAct or BestToWait. Ini-
tial knowledge or belief about the patient’s status is rep-
resented by a “prior probability” Pr(BestToAct), which 
could express a precise estimate or a subjective opinion. 
When there is treatment controversy, Pr(BestToAct) is 
too far from certainty (one or zero) to make the best clin-
ical decision clear to most physicians.
The intention is that some biomarker test yielding a 
positive (Pos) or negative (Neg) result will reveal some-
thing about the patient status, so that knowing the test 
result updates our knowledge, expressed by moving 
Pr(BestToAct) up or down using Bayes Theorem. Now, 
one decision challenge is replaced by two: for Pos and 
for Neg patients. The hope is that they will have clear 
and opposite decisions. (What “patient status” refers to 
receives some discussion later).
NNT and performance criteria for biomarker validation 
clinical trials
Laupacis et al. [20] introduced “number needed to treat”, 
NNT, to summarize results of antihypertensive therapy to 
reduce hypertension-related adverse events: how many 
patients needed to be treated in order to benefit one 
patient. They reported NNT = NNTNeg = 17 in patients 
without target-organ damage, and NNT  =  NNTPos  =  7 
with damage. The subscripts “Pos” and “Neg” come about 
by thinking of target-organ damage as “biomarker” test, 
positive if present, negative if absent. In that setting, 
the two NNT values described the size of the treatment 
effect in clinically relevant terms, for the “Pos” and “Neg” 
patient groups.
To use a NNT value in deciding whether to treat a 
patient, a physician needs to combine it with value judg-
ments weighing harms versus benefits accruing to dif-
ferent people. If NNT patients are all treated, and one 
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benefits, there are NNT − 1 “victims” not helped by the 
treatment. If none are treated, the NNT − 1 who should 
not receive the treatment are saved from it, but the one 
patient who would have been helped will not receive the 
help. Which of these two collective results on the NNT 
patients is best may be fairly termed an ethical judgment. 
(For convenience, this paper uses the term “ethical” in 
reference to value judgment tradeoffs, without imply-
ing that any particular action would deserve the epithet 
“unethical”).
Consider the example in Fig.  2. For NNT between 8 
and 16, some medical decision is ethically uncomfort-
able; treating all patients (“Act”) entails treating too many 
who do not need it, but withholding treatment for all 
(“Wait”) misses too many opportunities to help some of 
the patients. We call the interval (NNTLower, NNTUpper)   
=  (8, 16) the NNT discomfort range. Suppose the 
observed NNT for all the patients is 11. Treating all 11 
means helping one (a BestToAct patient), but subjecting 
the other ten to treatment without benefit (BestToWait). 
Requirements:
Predictive Values
Bayes concept:  
    "Posterior Probabilities"
Conditional on:
      Observed biomarker value
Contra-Bayes 
Theorem
Requirements:
Number Needed to Treat
(NNTLower, NNTUpper)
Requirements:
Sensitivity, Specificity
Bayes concept:      "Model"
Conditional on:   Unknown patient group
Prevalence of "BestToAct" group
Bayes concept: 
    "Prior probability"
Value judgment:
Ethics, compassion, cost, ...
Bayes concept: 
    "Loss function", 
    "Utility function" 
STUDY DESIGN
Prospective:  Cohort Study
Sample size:    Large
STUDY DESIGN
Retrospective:  Case/control
Sample size:   Small
Fig. 1 Roadmap for biomarker validation study design. Steps in the development of a study design for biomarker validation. Upper left-hand boxes 
judgments provided by clinical investigators. Lower right-hand boxes application of calculations of relevant quantities to the design of prospective 
(middle right) and retrospective (lower right) studies
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Being within the hypothetical discomfort range, this 
number implies a clinical decision dilemma. Suppose 
we now have a test separating patients into a Positive 
group, with NNT  =  NNTPos  =  7 and a Negative group 
with NNT =  NNTNeg =  17. Both values are outside the 
discomfort range. Then the physician will comfortably 
treat a patient in the Pos group, since eight is greater than 
NNTPos = 7. Since the physician also judges that treating 
more than 16 (NNTUpper) to help one BestToAct patient 
is too much unnecessary overtreatment, then they will 
comfortably refrain from treating a patient in the Neg 
group. The test information usefully informs the treat-
ment decision. Knowing the test information, combin-
ing the objective knowledge NNTPos and NNTNeg with the 
subjective discomfort boundaries NNTLower and NNTUpper 
converts an uncomfortable clinical decision into a clear 
decision for both Pos and Neg subgroups.
This paper proposes eliciting the NNT discomfort range, 
choosing desired values outside this range for NNTPos and 
NNTNeg in the test-positive and test-negative subgroups, 
and leveraging those values to guide the study design. This 
exercise helps the study team determine a relevant patient 
population and rules for selecting specimens, and ensure 
that the study’s eventual results will have utilitarian inter-
pretability for guiding clinical decisions.
To elicit the NNT discomfort range, we strip physician 
preferences down to the essentials. One guides the NNT 
respondent, typically the clinical principal investigator, to 
imagine a clinic schedule of patients, together with the 
certain knowledge that, if treated, exactly one will receive 
the benefit hoped for. With this scenario, all uncertain-
ties are removed, and all outcomes are known; the only 
thing unknown is which of the NNT patients will be 
the sole beneficiary. Framing the problem in terms of a 
fixed number of patients with fixed outcomes rather than 
probabilities or proportions circumvents the well-known 
documented numeracy deficiencies that plague even 
medical researchers [21, 22].
The immediate goal is to elicit a pure judgment about 
the value tradeoffs. With fixed, non-probabilistic out-
comes, making these judgments becomes simpler. The 
final goal is to describe desired performance require-
ments for a genuinely helpful clinical test. These require-
ments will feed the design of a meaningful clinical study.
Declaring values for NNTLower and NNTUpper requires 
courage, because it entails exposing one’s subjective valu-
ations trading off the benefits of helping versus the costs 
of overtreating. However, compared to declaring either 
probabilities or abstract disembodied “utility” tradeoffs, 
the concrete visualization of a group of patients and their 
outcomes is more likely to produce a meaningful answer. 
The burden of imagination is not so great, because there 
are no probabilities to guess at or interpret. The totality 
Table 1 Steps in  planning a retrospective biomarker vali-
dation study
“Scaffolding for NNT-guided protocol design” illustrates these study planning 
steps for a specific study
Stepping stone Question format
0 Classification rule development (Outside the scope of this article)
1 Defining the clinical scenario Who are the patients, what are 
the clinical options?
2 Principal goal What NNT s for the BestToAct and 
BestToWait groups  
would make the decision 
clear-cut?
3 Clinical benefit Specifically how will patients be 
helped by a test that achieves 
these NNT’s?
4 Classification performance 
needed
What predictive values do these 
NNT’s correspond to?
5 Prospective study requirements Given these NNT’s, how large 
should a prospective  
study be, and how long the 
follow-up?
6 Retrospective study  
requirements
Given a prevalence, what 
sensitivity and specificity do 
we hope for, and what should 
the sample sizes be to estimate 
them sufficiently?
Fig. 2 NNT and clinical decisions. On the left is a single patient for whom it is “Best to act”, indicated by the “thumb’s up” sign. The horizontal scale 
refers to the number of patients needed to treat (NNT) in order to help one. The range [NNTLower, NNTUpper] should describe a range of discomfort 
with either decision, Act or Wait
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of the outcomes is fixed; not just the benefits but also any 
costs or side effects associated with treating the patients 
would already be taken into account in the imagination 
of the NNT respondent, just as they are when making a 
clinical decision for a real patient.
The NNT framework helps to ground in the real world any 
discussion of what would make a clinical test truly useful. 
Prior to discussing an NNT discomfort zone, one respond-
ent stated that PPV = 15 % and NPV = 70 % would be suf-
ficient for a useful test, perhaps deliberately setting a low 
bar. Many people might notice that these values are unambi-
tious. It may not be instantly obvious that they do not even 
make sense. That becomes clear after translating to NNTLower  
=  1/0.15 =  6.7 and NNTUpper =  1/(1 −  0.70) =  3.3, since 
NNTLower must be smaller than NNTUpper. In another set-
ting, the stated desired performance was sensitivity = 30 %, 
specificity = 70 %, a performance achievable with a weighted 
random coin flip. Thus, elicitations of desired test perfor-
mance not using NNT ideas can be problematic even among 
researchers. Brawley’s discussions [23] of the ethical issues 
in radical prostatectomy and screening in prostate cancer 
are instructional. He uses observed NNT values explicitly 
to shed light on whether the NNT is too large to warrant 
treatment or screening; in our terms, bigger than NNTUpper. 
Anyone capable of judging whether an observed NNT is too 
large or too small for a comfortable decision should also be 
capable of setting an NNT discomfort range.
The study contemplated is to validate a biomarker test 
separating patients into two subgroups, Pos and Neg. The 
desired clinical performance is described by
If the study finds that the biomarker test achieves the 
outer inequalities, then the test has a good opportunity 
to improve patient care; otherwise, little chance. With-
out the biomarker, the actual NNT for the entire group 
of subjects might be lower than NNTLower, higher than 
NNTUpper, or in between. Each of these three scenar-
ios presents a distinct opportunity to improve clinical 
practice. For the current exposition, we focus on the “in 
between” case, illustrated in Fig. 2.
Mapping from NNT range to predictive values 
for prospective study design
NNT maps directly to the familiar concepts positive and 
negative predictive values (PPV and NPV). We visual-
ize the aftermath of successful validation studies, when 
a useful test has been developed, with NNTPos and 
NNTNeg as the estimated NNT values for Pos and Neg 
patients. Then in a group of NNTPos treated test-positive 
patients, one of them will benefit. This patient is a “true 
(1)
NNTPos < NNTLower < NNTUpper
︸ ︷︷ ︸
discomfort range
< NNTNeg .
positive”, so the positive predictive value, PPV, is 1/NNT-
Pos. Among NNTNeg patients with Neg results, none of 
whom are treated, one of them would have benefitted if 
treated, constituting a “false negative”. Therefore NPV is 
1 − 1/NNTNeg. Combining the requirements for a useful 
test (Eq. 1) with these mappings, we need
To plan a prospective validation study, one chooses the 
desired precision for estimating PPV and NPV and con-
firming NNTPos < NNTLower and NNTUpper < NNTNeg to a 
desired level of confidence. Then the usual biostatistical 
considerations determine the minimum sizes of the Pos 
and Neg subgroups, for whatever standard or nonstand-
ard study design is desired. Because the study is pro-
spective, only the overall sample size is controlled; the 
proportions of Pos and Neg patients are not (unless the 
test is quantitative and the categories are adjustable by 
moving a continuous cutoff, not discussed in this paper).
Retrospective studies: mapping from desired predictive 
values to desired sensitivity and specificity
Because of the cost, size and extended duration of a pro-
spective study, a retrospective case–control study usually 
comes first. Assembling a sample of cases for a retrospec-
tive case–control study means identifying people who, 
in hindsight, are known to be in the BestToAct category: 
patients who were not treated but (we now know) should 
have been treated. The controls are from the BestToWait 
category: untreated patients with good outcomes, or else 
treated patients who were not helped.
A key design challenge is to decide the sample sizes for 
selected cases and controls, the BestToAct and BestToWait 
patients. The case–control study will then determine the 
test status, Pos or Neg, for each subject. These data will pro-
vide the estimates of the sensitivity (SN) and specificity (SP). 
To choose sample sizes for the validation study, what SN and 
SP values correspond to the clinical usefulness we seek?
Bayes theorem uses SN and SP, together with the 
prevalence, to generate PPV and NPV. However, we 
now need to go in reverse, from required PPV and 
NPV to required SN and SP. In terms of the prior odds, 
Odds = Pr(BestToAct)/Pr(BestToWait), the “positive pre-
dictive odds” PPO =  PPV/(1 −  PPV), and the “negative 
predictive odds” NPO = NPV/(1 − NPV), we have a “con-
tra-Bayes” theorem:
(This has a meaningful solution whenever the positive 
and negative test results change the prior odds in the 
(2)PPV > 1/NNTLower , NPV > 1−1/NNTUpper .
(3)
SP = specificity =
PPO − Odds
PPO − NPO−1
SN = sensitivity =
NPO − Odds−1
NPO − PPO−1
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expected directions: PPO  >  Odds  >  NPO−1. Additional 
file  1 demonstrates verification of Eq.  3 by simple alge-
braic substitution and simplification.)
Figure  3 shows regions where the solution to Eq.  3 
yields a feasible sensitivity/specificity pair. The left-side 
boundary of the feasible region is defined by sensitiv-
ity  =  prevalence; the bottom boundary is defined by 
specificity = 1 − prevalence. The steeply slanted red lines 
are contours of constant sensitivity. The gently slanted 
blue lines are contours of constant specificity.
The black line connecting the lettered labels marks 
points where the sensitivity equals the specificity. See 
Table  2 for values at these points. Point A corresponds 
to a purely random “test”. Point F corresponds to a per-
fect test. The left-side boundary of the feasible region is 
defined by sensitivity = prevalence; the bottom boundary 
is defined by specificity = 1 − prevalence. For example, 
in Fig.  3c, beginning at point D (sensitivity  =  specific-
ity = 0.80), climbing the steep red line increases the spec-
ificity only, and improves NNTNeg over 150, while 
improving NNTPos negligibly.
Results
Scaffolding for NNT‑guided protocol design
Table 1 presents key questions and steps along the path 
to a biomarker validation study design. A consultation 
in which this author participated illustrates these steps, 
in a relatively simple setting. Step 1 Clinical scenario: 
Prognosis of cutaneous T cell lymphoma (CTCL). In 
early stages of CTCL, patients (Stages IA-IIA) usually 
do well and have slowly progressive disease, which does 
not require aggressive therapy associated with substan-
tial side effects. However, about 15  % of these patients 
have unexpected progressive course and rapid demise. 
Step 2 Principal goal: To identify, among patients who 
are diagnosed with early stage CTCL, who should receive 
the aggressive therapy immediately. Step 3 Clinical ben-
efit: A biomarker progression risk model that is able to 
classify patients into high and low risk groups will ena-
ble personalized and more aggressive therapy for the 
patients at highest risk for progression. Step 4 Classi-
fication performance needed: Regarding more aggres-
sive therapy upfront, the PI stipulates that the classifier 
will have clinical utility if the “number needed to treat” 
(NNT) is less than NNTLower  =  2 in the test-positive 
patients, and greater than NNTUpper  =  30 in the test-
negative patients. Then two patients testing positive will 
need to receive aggressive treatment upfront in order to 
treat one patient who otherwise would suffer later rapid 
progressive CTCL, while in the test-negative patients one 
would have to treat an unacceptably high 30 patients to 
treat one patient in advance of progressive CTCL. This 
performance should suffice to create a clinical consensus 
supporting using the test for clinical decisions. Step 5 
Prospective study requirements: The values NNTLower = 2 
and NNTUpper = 30 correspond to the positive predictive 
value PPV =  50  % =  1/NNTLower, and the negative pre-
dictive value NPV = 97 % = 1 − 1/NNTUpper. We will be 
able to recruit 40 patients in this early-stage group, over 
3  years, with a minimum of 2  years follow-up thereaf-
ter. If the test divides the 40 patients into roughly 25  % 
positive and 75  % negative, and the estimates match 
the hoped-for values 2 and 30, the confidence intervals 
would be 19–81  % for PPV, and 83–100  % for NPV, or 
equivalently [24] 1.23–5.35 for NNTPos, and 5.81–1180 
for NNTNeg. The very wide confidence interval for PPV 
is due to the low sample size and low prevalence com-
bined with the low value for NNTPos, which is strongly 
weighted towards avoiding unnecessary aggressive ther-
apy. To obtain a more accurate and independent esti-
mate of PPV, we also plan a retrospective study. Step 6 
Retrospective study requirements: Combining PPV and 
NPV with an incidence of rapid progression of 15 %, the 
required sensitivity (SN) and specificity (SP) are 83.3 and 
85.3  %, respectively (contra-Bayes Theorem). To get a 
sense of the accuracy of anticipated estimates in the ret-
rospective (case/control) portion of the study, we con-
sider anticipated results for samples sizes 22 cases (the 
entire complement of early stage CTCL who rapidly pro-
gressed) and 40 controls. For example, if the estimates 
SN = 18/22 = 82 % and SP = 34/40 = 85 % are observed, 
then the corresponding confidence intervals will be 
60–95 % for SN, and 70–94 % for SP, and Bayes predic-
tive intervals will be (1.4, 2.7) for NNTPos, and (16.4, 87.8) 
for NNTNeg. (These intervals derive from assuming inde-
pendent Jeffreys priors for SN and SP, sampling from 
joint independent posteriors incorporating the antici-
pated results, and applying Bayes theorem).
Steps 1 through 3 of the NNT scaffold force us to state 
the clinical dilemma that the biomarker is intended to 
help resolve. Step 4 is the critical ethics-balancing step 
that the NNT-based visualization supports. A reader 
might find fault with the clinical judgments expressed in 
steps 1 through 4, and that is exactly the point: exhibiting 
answers to these questions explicitly facilitates meaning-
ful discussion and critique. Steps 5 and 6 provide the sta-
tistical designs. Taken together, the scaffold allows us to 
judge whether these prospective and retrospective study 
designs adequately address the dilemma. Because of the 
NNT focus, after the study finishes, a published report 
can describe the potential for impact on clinical care in 
clinically visualizable and meaningful terms.
Several ways to improve the above statistical design 
and analysis plan come to mind, for example doing a sen-
sitivity analysis with regard to assumptions, polling mul-
tiple clinicians for their personal NNTLower and NNTUpper 
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values, incorporating risk factors, and supplementing 
with power calculations. These issues are beyond the 
scope of this article.
Thinking critically about what constitutes a BestToAct 
patient
An application of the NNT method to an endometrial 
cancer biomarker study illustrates how NNT thinking 
clarifies whether a new biomarker test has a realistic goal 
for helping patients. Defining what constitutes a Best-
ToAct patient is the challenge that brings this question 
to focus. It affects whether a biomarker study should be 
done at all.
A biomarker study to predict regional metastasis of 
endometrial cancer was under discussion. The overall 
purpose was to guide community oncologists and sur-
geons concerning whether to refer a case to a gyneco-
logic oncology surgeon, a specialist with in-depth 
experience with surgical staging of endometrial can-
cer. An observational study had suggested that referral 
for intensive surgical staging could improve survival in 
high-risk patients [25]. However, around 75 % of endo-
metrial cancer patients are Stage 1, generally curable 
with surgery alone; less than 20  % overall die of the 
disease before 5  years; and the clinical value of other 
treatment options for preventing or treating recurrent 
disease has little high-quality evidence [26]. Therefore 
room for improving patient outcomes is somewhat 
limited.
Most women diagnosed with endometrial cancer 
receive their diagnosis through oncologists who are not 
specialists in gynecological oncology. Most of these are 
cured by primary surgery performed by general surgeons 
or general cancer surgeons. However, some of these 
patients have nodal metastasis outside the region that 
the nonspecialist surgeon would be likely to examine, 
but within a region that extensive surgical staging might 
discover.
In a small proportion of cases, community oncologists 
make referral to gynecologic cancer surgery specialists. 
Perhaps a biomarker test would guide them to referral 
more often. The NNT perspective can help determine 
whether a biomarker study to identify patients at high 
risk for metastasis should proceed, because it impels 
the clinical researcher to examine how such a test might 
benefit patients. One cannot consider the value of a “true 
positive” in isolation from subsequent decisions and 
outcomes. If a test is positive, and leads to an “action” 
of referral for extensive surgical staging, what happens 
next? Patients may belong to one of these categories:
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Fig. 3 Contra-Bayes mapping from predictive values to sensitivity 
and specificity. See text and Table 2 for details. The points labeled A 
through F correspond to sensitivities and specificities given in Table 2 
lines 1 and 2. a Values from Table 2 lines 3 through 6; b, c values from 
Table 2 lines 7 through 10. c uses NNT axes in place of predictive 
value axes. An interactive web application “shinyContraBayes” [29] is 
available, and also embedded in a more comprehensive application 
“shinyCombinePlots” [30]
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#1 No disease discoverable by extensive staging.
#2 Disease discoverable during excision of the primary 
in a community setting.
#3 Disease discoverable by extensive staging only.
To apply the NNT view, we again imagine a collection 
of NNT patients who will all be referred, or none referred, 
for surgical staging, with one patient in category #3, our 
tentative definition of BestToAct. An experienced gyneco-
logic oncologist can imagine the range and frequency of 
negative consequences from the referral and extensive 
surgery to patients in categories 1 and 2. A harder task 
is to project the benefit to the one patient whose special-
ized surgery reveals metastasis. This is because the third 
group further divides into:
#3a  Patients whose subsequent treatment will not 
change despite the finding.
#3b  Patients whose subsequent treatment will intensify, 
but without patient benefit.
#3c  Patients whose subsequent treatment will intensify, 
and the patient will benefit.
Therefore the choice whether to refer all NNT patients 
is not a pure ethical choice; to justify the decision, we 
still have to consider the probability that the category 
#3 patient is in category #3c. If the chance that the one 
group 3 patient is of type 3c is small, then one would 
demand a small NNT. The goal of eliciting NNT level rep-
resenting a pure ethical assessment is not achieved yet; a 
probability is still involved.
Only a patient in group #3c will benefit, while the detri-
ment of subjecting the other patients to more extensive 
surgery seems the same in groups #1, 2, 3a, or 3b. A rea-
sonable change, therefore, is to reframe the question so 
that, of the NNT patients, exactly one is in category #3c, 
our revised definition of BestToAct. Then a larger NNT is 
acceptable, because the benefit to that patient is definite. 
However, the “prevalence”, the probability of being in the 
group that actually benefits, is much smaller. Recall that 
for designing a retrospective study, the contra-Bayes the-
orem requires this prevalence. It may be much easier to 
estimate the prevalence of an intermediate outcome like 
#3 than a truly relevant outcome like #3c. In this exam-
ple, arguably an inaccurate estimate of the clinically rel-
evant prevalence is better than an accurate estimate of 
a prevalence irrelevant to patient benefit. The goal, after 
all, is to deliver real benefits to patients, not just to gener-
ate usage of tertiary surgeries. To target a biomarker test 
at the achievement of real clinical benefit, the one patient 
who is the beneficiary among the NNT patients must 
truly benefit. If this principle guides the steps of the NNT 
scaffold and resulting discussion of NNTLower and NNTUp-
per, sometimes a compelling conclusion will be that the 
biomarker validation study contemplated has no chance 
of delivering a clinical improvement.
Discussion and conclusion
Open-source software to support the process described 
here is freely available as a published R package NNT-
biomarker [27], and also for immediate interactive use: 
shinyElicit [28], shinyContraBayes [29], shinyCombine-
Plots [30], and shinyAE [31].
Upon reporting completed trial results, the NNT 
method suggests comparing estimates of NNTPos and 
NNTNeg to the edges of the discomfort zone, which 
should have been declared when the study was planned. 
Therefore, confidence intervals or predictive intervals for 
anticipated NNTPos and NNTNeg results are clinically rele-
vant. P values for testing a “no-difference” null hypothesis 
Table 2 Connecting sensitivity, specificity, and prevalence, to predictive values and NNT values
Circled letters refer to points labeled in Fig. 3. Example: for column D, if the test sensitivity and specificity both equal 0.80, and the prevalence is 0.05, then the 
predictive values for the test are respectively 0.17 and 0.99 (point D graphed in Fig. 3b), and the NNT values in the positive and negative test groups are respectively 
5.8 and 77.0 (point D graphed in Fig. 3c)
A B C D E F
Sensitivity 0.50 0.60 0.70 0.80 0.90 1.00
Specificity 0.50 0.60 0.70 0.80 0.90 1.00
PPV 0.50 0.60 0.70 0.80 0.90 1.00 Prevalence = 0.5 (see Fig. 3a)
NPV 0.50 0.60 0.70 0.80 0.90 1.00 Prevalence = 0.5 (see Fig. 3a)
NNTPos 2.0 1.7 1.4 1.3 1.1 1.00 Prevalence = 0.5 (see Fig. 3a)
NNTNeg 2.0 2.5 3.3 5.0 10.0 Inf Prevalence = 0.5 (see Fig. 3a)
PPV 0.05 0.07 0.11 0.17 0.32 1.00 Prevalence = 0.05 (see Fig. 3b, c)
NPV 0.95 0.97 0.98 0.99 0.99 1.00 Prevalence = 0.05 (see Fig. 3b, c)
NNTPos 20.0 13.7 9.1 5.8 3.1 1.00 Prevalence = 0.05 (see Fig. 3b, c)
NNTNeg 20.0 29.5 45.3 77.0 172.0 Inf Prevalence = 0.05 (see Fig. 3b, c)
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or a bioequivalence null hypothesis have their place, but 
are remote from communicating the biomarker’s clinical 
utility potential.
The application of NNT elicitation to develop objectives 
for biomarker studies sometimes involves challenging 
complications. A subset of them touch on timing of sam-
ple acquisition for biomarker assessment. Consider select-
ing samples when the setting is such that “BestToAct” 
samples represent occurrences of a future event that one 
wants to prevent. Frequently, the availability of conveni-
ence samples taken at the time of the future event impels 
investigators to use those samples as “cases”. This is prob-
lematic, because that time point does not coincide with 
the time point at which the biomarker would be used for 
the guiding medical decision, typically years earlier. If we 
are lucky, the biomarker does not change over time (for 
example, it may define a separate etiology and so be pre-
sent from inception of the disease). Then a study confirm-
ing a biomarker using convenience samples from around 
the time of the event would validly reflect its usefulness 
for clinical practice, even though the time the Act/Wait 
clinical decision must be made is much earlier. However, 
the biomarker may appear gradually as the disease devel-
ops, prior to diagnosis but after the intended time of clini-
cal decision. Then even a very strong positive predictive 
value for a measurement just prior to the event we want 
to prevent or prepare for may be useless; the biomarker 
would not yet be positive when the decision had to be 
made. This distinction, though obvious, is frequently over-
looked. Even if the biomarker is present from the begin-
ning, the sample defining the the patient group (“it would 
have been BestToAct/BestToWait”) is sometimes the same 
sample used to assess the biomarker. Patient’s classifica-
tion and the patient’s biomarker value will have an extra 
spurious source of correlation due to variation from spa-
tial sampling of tissue. Banked samples can eliminate this 
risk. For example, the Oncotype DX® test was developed 
on banked samples, using microarray technology that was 
sufficiently accurate on paraffin-embedded primary can-
cer tissue. This tissue hailed from primary surgery, a time 
point in the clinical history near where decisions about 
adjuvant treatment would be made.
A related dilemma occurs when the desire is to develop 
a predictor for early-stage patients, but the available 
samples are from advanced-stage patients. One might 
also deliberately select advanced-stage patients, hop-
ing that the signal we seek will be that much stronger in 
advanced-stage patients, so a good biomarker might be 
detected with a smaller sample size. This may be wish-
ful thinking. Any step causing the study’s setting to dif-
fer from the hoped-for clinical decision setting where 
we want to deploy to test will risk irrelevancy. The NNT 
perspective puts the focus on the patients one hopes 
eventually to help with the test. This focus can prevent 
questionable research strategies.
This article only deals with binary biomarkers. We have 
also studied the NNT method in the context of continu-
ous-valued biomarkers, specifically gene expression tests 
in breast cancer. The topic is an important extension, but 
beyond the scope of this article. A visual tool to examine 
consequences of treating for each recurrence score value 
is available [31]; the display is elaborated with informa-
tion on adverse event outcomes as well.
The NNT-based approach presented here bears resem-
blance to the traditional threshold-based clinical decision 
methods [17, 19]. However, the approach here differs in 
two ways: by using NNT to circumvent subjective proba-
bility-based inputs, and by using two thresholds NNTLower 
and NNTUpper, rather than one. Two thresholds are nec-
essary for defining the required operating characteristics 
of the study designs, as we have seen.
Sinclair et al. [19] studied NNT in the context of treat-
ing to prevent a bad outcome (“target event”, TE). They 
define a threshold for NNT, below which the preven-
tive treatment should be given despite adverse events 
(AE) from the treatment. They show how to calculate 
the threshold from various costs and relative values. The 
proposal here shares some of this spirit, with important 
differences. First, our purpose here is to guide design of 
a clinical trial, not to evaluate an established treatment. 
Second, our use of NNT is to craft a story to elicit the rel-
ative value of the outcomes, which in the previous frame-
work is just assumed known (TE relative to AE). Third, 
the choice of terminology in our framework allows it to 
apply across a wide variety of types of clinical decisions, 
not just preventing TEs.
Individual patients have their own relative valuations 
of the outcomes, which may differ in the test deployment 
situation from the idealization of the investigator plan-
ning the test validation study years earlier. To personalize 
each medical decision, honoring each patient’s individual 
circumstance and personality, is part of the art of medi-
cine. As important as these considerations are, they can-
not help in the study design phase; at that stage, thinking 
about patients in the abstract is necessary. It is certainly 
superior to thinking about statistical criteria remote from 
patient benefits and risks.
The impact of biomarkers on clinical medicine has been 
disappointing despite the extraordinary advance of molec-
ular medicine and sophisticated high-throughput assays. 
The technique explored in this paper can contribute to the 
translational research process, guiding us towards interven-
tions of real clinical benefit, by bringing concrete assess-
ment of ethical tradeoffs to the definition of clinical utility.
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